The key catalyst is the FDA feedback in Q4 2026 on the new brilaroxazine formulation, which will determine the path for the RECOVER-2 trial and NDA. The company's cash runway and ability to secure additional financing before 1H 2027 enrollment are critical to monitor.
Drugs in focus
RVPH drug pipeline →brilaroxazine
◆ Mixed Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If approved, brilaroxazine is at least 3-5 years from potential commercialization. RECOVER-2 enrollment is expected to begin in 1H 2027 (subject to financing), followed by a multi-year trial, NDA submission, and FDA review.
- Next catalyst
- None dated
What to watchThe immediate catalyst is FDA feedback on the new brilaroxazine formulation, expected in Q4 2026 (any day now). Positive feedback would clear a path for RECOVER-2 and NDA; negative feedback or a request for more data would likely pressure the stock further. Separately, the company needs to raise additional capital before RECOVER-2 enrollment can begin in 1H 2027, and its OTCQB listing limits financing options.
How the stock moved after the report
NEUTRAL VIEWSTOCK AT ENTRY AT T+60- T+0 · Aug 13 $0.3521entry
- T+1 · 3mo ago 0.00%α +0.20% · $0.3521
- T+5 · 3mo ago 0.00%α +1.96% · $0.3521
- T+20 · 2mo ago 0.00%α +1.75% · $0.3521
- T+60 · 11d ago 0.00%α +5.48% · $0.3521
Price Chart
How similar events traded
Executive Summary
Reviva Pharmaceuticals reported a Q2 2026 net loss of $2.4 million ($0.19 per share), narrower than the year-ago loss of $6.1 million ($2.40 per share), and ended the quarter with $19.9 million in cash. The company is awaiting FDA feedback in Q4 2026 on using a new brilaroxazine formulation in its RECOVER-2 Phase 3 trial and NDA, with patient enrollment expected to begin in 1H 2027 subject to additional financing.
Key Financial Metrics
Key Facts
- Net loss of $2.4 million ($0.19 per share) for Q2 2026 vs. $6.1 million ($2.40 per share) for Q2 2025.
- Cash and cash equivalents of $19.9 million as of June 30, 2026, up from $14.4 million as of December 31, 2025.
- FDA feedback on new brilaroxazine formulation for RECOVER-2 trial and NDA expected Q4 2026.
- Patient enrollment in RECOVER-2 Phase 3 trial expected to initiate in 1H 2027, subject to additional financing.
- U.S. composition of matter patent application filed for a new form of brilaroxazine, aiming to extend exclusivity through 2046.
Financial Impact
Net loss improved by $3.6 million year-over-year; cash position increased by $5.5 million since year-end 2025.
Risk Factors
- Patient enrollment in RECOVER-2 is contingent on additional financing, which may not be secured.
- The company's stock trades on OTCQB, which may limit liquidity and access to capital.
- No revenue generated; reliance on dilutive financing to fund operations.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344112 |
Track record
12 reports on RVPH
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 No price data
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3400 Now $0.3504 +3.07% settles Feb 11
- Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
- Aug 12, 202613w ago Press Release Neutral 4/10 Viewing Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
- Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
- May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
- May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
- Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
- Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
- Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers